| Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ... Nature genetics 45 (4), 371-384, 2013 | 625 | 2013 |
| Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline AA Wright, K Bohlke, DK Armstrong, MA Bookman, WA Cliby, ... Gynecologic oncology 143 (1), 3-15, 2016 | 589 | 2016 |
| Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations R Salani, FJ Backes, MFK Fung, CH Holschneider, LP Parker, RE Bristow, ... American journal of obstetrics and gynecology 204 (6), 466-478, 2011 | 426 | 2011 |
| Identification of six new susceptibility loci for invasive epithelial ovarian cancer KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ... Nature genetics 47 (2), 164-171, 2015 | 289 | 2015 |
| Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study D Tewari, JJ Java, R Salani, DK Armstrong, M Markman, T Herzog, ... Obstetrical & Gynecological Survey 70 (8), 505-506, 2015 | 278 | 2015 |
| Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early-stage endometrial cancer ME Randall, V Filiaci, DS McMeekin, V Von Gruenigen, H Huang, ... Journal of Clinical Oncology 37 (21), 1810, 2019 | 252 | 2019 |
| An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations R Salani, N Khanna, M Frimer, RE Bristow, L Chen Gynecologic oncology 146 (1), 3-10, 2017 | 244 | 2017 |
| Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome R Salani, A Santillan, ML Zahurak, RL Giuntoli, GJ Gardner, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2007 | 189 | 2007 |
| Cancer and pregnancy: an overview for obstetricians and gynecologists R Salani, CC Billingsley, SM Crafton American journal of obstetrics and gynecology 211 (1), 7-14, 2014 | 164 | 2014 |
| Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug … R Salani, RJ Kurman, R Giuntoli, G Gardner, R Bristow, TL Wang, IM Shih International Journal of Gynecologic Cancer 18 (3), 2008 | 161 | 2008 |
| Amplicon profiles in ovarian serous carcinomas K Nakayama, N Nakayama, N Jinawath, R Salani, RJ Kurman, IM Shih, ... International journal of cancer 120 (12), 2613-2617, 2007 | 156 | 2007 |
| A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival K Nakayama, N Nakayama, B Davidson, JJC Sheu, N Jinawath, ... Proceedings of the National Academy of Sciences 103 (49), 18739-18744, 2006 | 140 | 2006 |
| Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status R Salani, I Puri, RE Bristow American journal of obstetrics and gynecology 200 (2), 182. e1-182. e5, 2009 | 127 | 2009 |
| BRCA mutation in ovarian cancer: testing, implications and treatment considerations RT Neff, L Senter, R Salani Therapeutic advances in medical oncology 9 (8), 519-531, 2017 | 125 | 2017 |
| Breast and gynecologic cancer-related extremity lymphedema: a review of diagnostic modalities and management options P Tiwari, M Coriddi, R Salani, SP Povoski World journal of surgical oncology 11, 1-13, 2013 | 115 | 2013 |
| Do survivorship care plans impact patients' evaluations of care? A randomized evaluation with gynecologic oncology patients BM Brothers, A Easley, R Salani, BL Andersen Gynecologic oncology 129 (3), 554-558, 2013 | 99 | 2013 |
| Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer R Salani, A Axtell, M Gerardi, C Holschneider, RE Bristow Gynecologic oncology 108 (2), 271-275, 2008 | 99 | 2008 |
| Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival CM Cosgrove, DE Cohn, H Hampel, WL Frankel, D Jones, JP McElroy, ... Gynecologic oncology 146 (3), 588-595, 2017 | 89 | 2017 |
| Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants DR Barnes, MA Rookus, L McGuffog, G Leslie, TM Mooij, J Dennis, ... Genetics in Medicine 22 (10), 1653-1666, 2020 | 79 | 2020 |
| NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021: Featured Updates to the NCCN Guidelines NR Abu-Rustum, CM Yashar, K Bradley, SM Campos, J Chino, HS Chon, ... Journal of the National Comprehensive Cancer Network 19 (8), 888-895, 2021 | 77 | 2021 |
